Apotex has received Health Canada approval for its Bambevi (bevacizumab) biosimilar rival to Avastin, with the Canadian giant’s Apobiologix unit billing the product as “its first therapeutic treatment.”
Apotex Breaks New Ground In Canada With Biosimilar Bevacizumab
Apobiologix Unit Receives Health Canada Approval For Bambevi Rival To Avastin
Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.
